Details

Autor(en) / Beteiligte

• Zaniboni, Alberto, MD
• Bertocchi, Paola, MD
• Barni, Sandro, MD
• Petrelli, Fausto, MD

Titel

TAS-102 (Lonsurf) for the treatment of metastatic colorectal cancer. A Concise review

Ist Teil von

• Clinical colorectal cancer, 2016-12, Vol.15 (4), p.292-297

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Within the last several years, no chemotherapy has been sufficient to increase the overall survival of patients with chemorefractory colorectal cancer. TAS-102 (Lonsurf®) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs, trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor). This drug extended the median overall survival by approximately 2 months compared with placebo in a randomized phase III trial composed of Asian and non-Asian patients with refractory (or intolerant) metastatic colorectal cancer. The clinical development of TAS-102 began about a decade ago and included two pivotal randomized studies, which will be discussed in this review. This drug has just been approved in Japan, and as soon as possible, it will be marketed in Western countries as well; it will therefore become the standard of care for this patient population. The optimal combination of TAS-102 with other agents as well as the mechanism of resistance to this regimen should be defined in the near future.